Tenascin-C targeting strategies in cancer

•Tenascin-C is highly expressed in cancer generating immune suppressive niches.•Tenascin-C is used as tumor biomarker and as zip code for delivery of therapeutic agents.•Tenascin-C is targeted by a huge arsenal of versatile molecular tools.•Numerous clinical trials are supporting tenascin-C targetin...

Full description

Saved in:
Bibliographic Details
Published in:Matrix biology 2024-06, Vol.130, p.1-19
Main Authors: Dhaouadi, Sayda, Bouhaouala-Zahar, Balkiss, Orend, Gertraud
Format: Article
Language:English
Subjects:
Antibody
Aptamer
Biomarker
Cancer
Diagnostic application
Extracellular matrix
Inflammation
Life Sciences
Nanobody
Peptide
Tenascin-C
Therapeutic approach
Tumor
Tumor immunity
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Tenascin-C is highly expressed in cancer generating immune suppressive niches.•Tenascin-C is used as tumor biomarker and as zip code for delivery of therapeutic agents.•Tenascin-C is targeted by a huge arsenal of versatile molecular tools.•Numerous clinical trials are supporting tenascin-C targeting as clinical option.•Targeting tenascin-C immune suppression offer novel targeting opportunities. Tenascin-C (TNC) is a matricellular and multimodular glycoprotein highly expressed under pathological conditions, especially in cancer and chronic inflammatory diseases. Since a long time TNC is considered as a promising target for diagnostic and therapeutic approaches in anti-cancer treatments and was already extensively targeted in clinical trials on cancer patients. This review provides an overview of the current most advanced strategies used for TNC detection and anti-TNC theranostic approaches including some advanced clinical strategies. We also discuss novel treatment protocols, where targeting immune modulating functions of TNC could be center stage.
ISSN:0945-053X
1569-1802
1569-1802
DOI:10.1016/j.matbio.2024.04.002